174 patents currently held
34 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Nov 2028
Next term end
155
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Oct 2036 · Medium confidence
Also notable
Ends Nov 2034 · High confidence
Also notable
Ends Oct 2032 · High confidence
Also notable
Ends Jun 2039 · High confidence
Also notable
Ends Apr 2037 · High confidence
Also notable
Ends Dec 2037 · High confidence
Also notable
Ends Mar 2036 · High confidence
Also notable
Ends Mar 2031 · High confidence
Methods and Products for Genetic Engineering
US 11,649,264
Cited by 19 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Methods and Pharmaceutical Compositions for the Treatment of Hepatitis B Virus Infection
US 9,895,380
Cited by 44 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Antibodies Directed Against ICOS and Uses Thereof
US 9,376,493
Cited by 28 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Nipah virus envelope glycoprotein pseudotyped lentivirus
US 11,608,509
Cited by 21 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
Device and System for Generating Ultrasonic Waves in a Target Region of a Soft Solid and Method for Locally Treating a Tissue
US 11,540,806
Cited by 38 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2037.
Lentiviral Vector Expressing Membrane-Anchored or Secreted Antibody
US 11,623,950
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2037.
Novel Antiviral Compositions for Treating the Flu
US 11,351,180
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2036.
Method of Embolization using a Radiopaque, Non-Biodegradable, Water-Insoluble Iodinated Benzyl Ether of PolyI(Vinyl Alcohol)
US 9,434,800
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2031.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Electrophysiological Method for Assessing the Effectiveness of a Hearing Aid (US 10,299,696) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 4, 2026The maintenance fee for Novel Silicone Composition Crosslinking Catalysts (US 10,308,770) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 4 fees due Jan 4 to 28, 2027 · next Jan 4
- 2 fees due Feb 22 to 28, 2027 · next Feb 22
- 1 fee due Mar 26, 2027The maintenance fee for Biocell with Fuel Reservoir (US 11,769,894) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 8 fees due Apr 1 to 30, 2027 · next Apr 1
- 3 fees due May 12 to 26, 2027 · next May 12
- 2 fees due Jun 19, 2027
- 6 fees due Jul 14 to 30, 2027 · next Jul 14
- 1 fee due Aug 18, 2027The maintenance fee for Sentinel Signal for Adaptive Retention Time in Targeted MS Methods (US 10,566,178) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 4 fees due Oct 2 to 28, 2027 · next Oct 2
- 2 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- 6 of the patents on this record were granted since Aug 23, 2026
- 2 terms have ended since Aug 23, 2026
- Nov 5 US 7,816,520 5,6-Diphenyl-1,2,4-Triazinic Dimeric Derivatives and the Use Thereof in the Form of Sun-Protective Agents · term ended
- Sep 11 US 10,071,108 Methods and Pharmaceutical Compositions for the Treatment of Hepatitis B Virus Infection · lapsed on the fee record
What they patent
The largest of its 155 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,357,545 | Hybrid Nanoparticles with LN2O3 Core and Carrying Biological Ligands, and Method of Preparation Thereof held by Universite Claude Bernard Lyon I, Centre National de la Recherche Scientifique (CNRS) and Institut National des Sciences Appliquees de Lyon In force · High confidence | In force | High confidence | |
| US 8,357,907 | Method and Device for Real-Time Measurement of a Local Dose Upon Bombardment of a Target by Hadrons by Means of Prompt Gamma Rays In force · High confidence | In force | High confidence | |
| US 8,481,691 | Method for Selectively Extracting Membrane Proteins Using Calixarenes In force · High confidence | In force | High confidence | |
| US 9,170,263 | Novel Method for Quantifying Proteins by Mass Spectrometry held by Biomerieux, Universite Claude Bernard Lyon I and Centre National de la Recherche Scientifique In force · High confidence | In force | High confidence | |
| US 9,018,580 | Method for Detecting Molecules Through Mass Spectrometry held by Biomerieux, Universite Claude Bernard Lyon I and Centre National de la Recherche Scientifique In force · High confidence | In force | High confidence | |
| US 8,802,425 | Method for the Hypothermic Perfusion of a Cardiac Organ, and Device for the Implementation Thereof held by Universite Claude Bernard Lyon I and Inserm (Institut National de la Sante et de la Recherche Medicale) In force · High confidence | In force | High confidence | |
| US 9,023,814 | Glycomimetic Compounds as Anti-Infectious Against Pathogens Lectins held by Centre National de la Recherche Scientifique, Universite Claude Bernard - Lyon 1 and Universite Lille 2 - Droit et Sante In force · High confidence | In force | High confidence | |
| US 8,778,341 | ANTI-CK8 Antibodies to Be Used for Treating Colorectal Cancers and Identifying Metastatic And/Or Invasive Phenotypes held by Universite Claude Bernard Lyon 1, Hospices Civils de Lyon and Centre National de la Recherche Scientifique (CNRS) In force · High confidence | In force | High confidence | |
| US 9,434,800 | Method of Embolization using a Radiopaque, Non-Biodegradable, Water-Insoluble Iodinated Benzyl Ether of PolyI(Vinyl Alcohol) held by Merit Medical Systems, Inc. In force · High confidence | In force | High confidence | |
| US 8,901,185 | A Hybrid Organic-Inorganic Material Constituted by a Silica Network Having Photochromic Agents and Optical Power Limiting Agents as a Doping Agent in the Material held by Universite Claude Bernard Lyon I, Centre National de la Recherche Scientifique and Foi Swedish Defence Research Agency In force · High confidence | In force | High confidence |
Also on record, not counted in the 174: 34 patents in force now held by others · 85 patents ended · 174 applications pending · 152 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.